We provide professional support in Radionuclide Therapies.
It is the most successful current imaging technology used
to evaluate the spread of prostate cancer to other organs or tissues. The
prostate-specific agent called PSMA binds to the gallium-68 radioisotope, and
is administered to the patient intravenously and a PET-CT imaging is performed.
Gallium-68 PSMA binds to some special molecules in prostate cancer cells and
enables visualization of cancerous tissues. In this method, radiation in very
high dose is not given to the patients.
Imaging should be scheduled a day in advance. Therefore,
an appointment is made. It is waited for 45 to 60 minutes after the agent is
administered intravenously. When the patient is in the device, the imaging
takes approximately 20 minutes and the patient should not move during this
period of time. The process can take a total of 2-3 hours in the Nuclear
Medicine Department. The patient is recommended to drink plenty of water before
and after the imaging. Since the radiation will remain in the body for a while
(8 to 12 hours) after imaging, it is necessary to be away from pregnant women
and children in particular.
It is the most advanced technology that can be used for
the diagnosis of neuroendocrine tumors. Neuroendocrine tumor cells have a
special receptor (sensory protein) called “somatostatin” on their surface.
DOTA-TATE is a peptide compound that can bind to these receptors. When it is
combined with a radioactive agent called “Gallium-68” and administered to the
patient, the tissues containing tumor cells can be visualized with high
accuracy on the PET-CT device. In this method, radiation in very high dose is
not given to the patients.
Lutetium-PSMA (177Lu-PSMA) therapy is an increasingly
used radionuclide therapy for patients with advanced stage prostate cancer. The
goal of this therapy is to reduce tumor size and stop the growth of tumor
cells. In this context, both the progression of the disease can be controlled
and it is possible to relieve advanced disease symptoms such as diffuse bone
pain and fatigue. This therapy is usually administered when the disease
progresses, spreads or when the side effects of other therapies such as chemotherapy
cannot be tolerated by the patient.
The radiation used in this therapy is designed to kill
cancer cells. Injected into the body, PSMA travels towards the tumor and
targets cancerous cells. Apart from prostate cancer cells, PSMA is also found
in tissues such as salivary glands, lachrymal glands and kidney. Therefore,
these tissues can also be exposed to radiation. However, this effect is low and
since PSMA adheres directly to cancer cells, it does not show the destructive
side effects of chemotherapy. Side effects such as dry mouth, temporary fatigue
or temporary decrease in blood values can be observed in some patients. These
effects can be controlled by blood tests performed at certain intervals in the
post-therapy period. In addition, patients who are likely to experience side
effects can be identified through tests before a treatment decision is made.
Personalized therapy strategies specific to each patient, supported by test
results and dosimeter studies, ensure that side effects are seen at the lowest
possible level.
Lutetium-Octreotide, [Lutetium-DOTA-TATE
(177Lu-DOTA-TATE)] therapy is an increasingly used therapy in patients with
advanced neuroendocrine cancer. Its another name is “Peptide Receptor
Radionuclide Therapy” (PRRT). The goal of this therapy is to reduce tumor size
and stop the growth of tumor cells. In this context, both the progression of
the disease can be controlled and it is possible to relieve advanced disease
symptoms such as diffuse bone pain and fatigue. This therapy is usually
administered when the disease progresses, spreads or when the side effects of
other therapies cannot be tolerated by the patient.
The radiation used in Lutetium-Octreotide therapy is
designed to kill cancer cells. Injected into the body, smart molecules
targeting somatostatin receptors target cancerous cells during their journey
towards the tumor. Apart from cancer cells, somatostatin receptors are also found
in many different organs. Therefore, these tissues can also be exposed to
radiation. However, this effect is low and, since smart molecules adhere
directly to cancer cells, they show none of the destructive side effects of
chemotherapy. Side effects such as temporary decrease in blood values can be
observed in some patients. These effects can be controlled by blood tests
performed at certain intervals in the post-therapy period. In addition,
patients who are likely to experience side effects can be identified through
tests before a treatment decision is made. Personalized therapy strategies
specific to the patient, supported by test results and dosimeter studies,
ensure that side effects are seen at the lowest possible level.
Radium therapy is a form of treatment used in patients in
whom prostate cancer has caused metastases to the skeletal system and bones.
The aim of this therapy is to destroy the cancer cells in the bones so allowing
the tumors to shrink or even disappear. In addition to its therapeutic effect,
it is also used to relieve pain caused by bone metastases.
Since the energy level of radiation used in radium
therapy is very high, its destructive power is very high. However, this
alpha-type radiation can travel very short distances due to its nature. By
short distance here is meant a length equal to the size of 2 to 10 cells.
Because of the properties of this alpha-type radiation, it destroys the cancer
cells in the bone and does not affect the healthy normal cells.
Post-therapeutic side effects are rare and usually cause a temporary decrease
in blood values. Therefore, patients should be checked at regular intervals
after treatment.
Ac-225 PSMA is the name of the radioactive agent administered
to the patient in targeted alpha therapy in prostate cancer. It is a therapy
form that can be used in metastatic advanced prostate cancer patients. The goal
of this therapy is to reduce tumor size, stop the growth of tumor cells and
destroy them. Radionuclide therapies are preferred during the treatment of
prostate cancer when the disease progresses, spreads or when other treatments
such as chemotherapy are ineffective or the side effects of the therapies are
not tolerated by the patient. As a general approach, Lutetium PSMA is the first
choice for patients who are decided on radionuclide therapy. Lutetium-PSMA is a
treatment method that has been administered to thousands of patients both in
Turkey and in the world. Reducing symptoms, extending life span and improving
quality of life are among the main goals of Lutetium-PSMA therapy. However,
despite Lutetium-PSMA therapy, some patients may not respond to therapy or the
response of the disease to therapy may be insufficient. The disease may even continue
to progress despite treatment. It has been shown in the medical literature that
targeted alpha therapies with Actinium-225-PSMA give much better results in
this group of patients.
The radiation used in actinium (AC-225) therapy is
designed to kill cancer cells. Injected into the body, PSMA travels towards the
tumor and targets cancerous cells. Apart from prostate cancer cells, PSMA is
also found in tissues such as salivary glands, lachrymal glands and kidney.
Therefore, these tissues can also be exposed to radiation. However, this effect
is very low and, since PSMA adhere directly to cancer cells, it shows none of
the destructive side effects of chemotherapy. Side effects such as dry mouth,
temporary fatigue or temporary decrease in blood values can be observed in some
patients. These effects can be controlled by blood tests performed and
examinations at certain intervals in the post-therapy period.
An institution that fueled dozens of worthwhile projects in Turkey, Anadolu Foundation made another dream real by founding Anadolu Medical Center.
Relying on the valuable heritage of Anatolia that boasts of thousands of years of medical knowledge and was home to many valuable people of medicine, our hospital uses this knowledge to contribute to human health.
Working in strategic cooperation with Johns Hopkins Medicine for the improvement of education and quality, our hospital provides services in all branches including in particular, oncologic sciences, cardiovascular health, gynecology and IVF, neurological sciences, surgical sciences, internal medicine, diagnosis and imaging.
Established on an area of 188.000 square meters and an indoor area of 50 thousand square meters with a capacity of 201 beds, our hospital provides services with JCI (Joint Commission International) accreditation, ESMO (European Society for Medical Oncology), ISO (18001, 14001 and 9001) certifications.
Anadolu Medical Center continues to provide healthcare services also at Ataşehir with its Outpatient Clinic. Procedural archives of patients who receive services at the Outpatient Clinic are kept in the virtual environment.
Having started to render service in June 2010 within the structure of the hospital, the Bone Marrow Transplantation Center performs bone marrow transplants for 22 patients at the same time. Our patients are always the number one priority at our hospital. For this reason, we give value to the needs and expectations of our patients, and make every effort to ensure that they have a peaceful treatment process and feel at home.
©2021 All rights reserved BookingDoctors™.
